Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTX 181

Next Previous
Drug Profile

TTX 181

Alternative Names: AAV9.hCLN2; RGX-181; TTX-181

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REGENXBIO
  • Developer Tern Therapeutics
  • Class Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference; Tripeptidyl-peptidase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuronal ceroid lipofuscinosis

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for clinical-Phase-Unknown development in Neuronal ceroid lipofuscinosis(In children) in Brazil (Intracisternal)
  • 08 Oct 2025 Preclinical trials in Neuronal ceroid lipofuscinosis in USA before October 2025 (Intracisternal) (Tern Therapeutics pipeline, October 2025)
  • 27 Aug 2024 RGX-181 licensed to Tern Therapeutics worldwide before August 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top